FMR LLC reports 1,800 shares of Centessa

FMR LLC files Amendment No. 4 to a Schedule 13G/A reporting ownership of 1,800 shares of Centessa Pharmaceuticals plc common stock.

Rhea-AI Filing Summary

FMR LLC files Amendment No. 4 to a Schedule 13G/A reporting ownership of 1,800 shares of Centessa Pharmaceuticals plc common stock. The filing lists the CUSIP 152309100, shows 1,800 shares beneficially owned representing 0.0% of the class, and names Abigail P. Johnson in the cover responses. Signatures are dated 07/07/2026.

Insights

Institutional Ownership Analyst

FMR LLC reports a de minimis stake of 1,800 shares in Centessa (0.0% of class).

Filing details are administrative: a Schedule 13G/A amendment showing beneficial ownership of 1,800 shares and identifying the filing parties, including Abigail P. Johnson. The CUSIP 152309100 and signature dates are provided.

Such small reported holdings typically do not signal a change in investment intent. Subsequent filings would show any material position changes or disclosures tied to larger ownership.

Key Figures

Shares reported beneficially owned: 1,800 shares Percent of class: 0.0% CUSIP: 152309100 +2 more

5 metrics

Shares reported beneficially owned 1,800 shares Schedule 13G/A Amendment No. 4

Percent of class 0.0% Reported on the cover responses

CUSIP 152309100 Centessa Pharmaceuticals plc common stock

Reporting/reference date 06/30/2026 Cover page date shown in metadata

Signature date 07/07/2026 Signed by authorized representative

Key Terms

Schedule 13G/A, beneficially owned, 13d-1(k)(1) agreement, power of attorney

4 terms

Schedule 13G/A regulatory

"Amendment No. 4 to Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Amount beneficially owned: 1800.00 (b) Percent of class: 0.0 %"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

13d-1(k)(1) agreement regulatory

"Please see Exhibit 99 for 13d-1(k)(1) agreement"

power of attorney other

"Power of Attorney effective as of April 13, 2026"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does FMR LLC report for CNTA ownership?

FMR LLC reports beneficial ownership of 1,800 shares of Centessa common stock. The filing states this equals 0.0% of the class and uses CUSIP 152309100, with signatures dated 07/07/2026.

Who is listed alongside FMR LLC on the Schedule 13G/A for CNTA?

Abigail P. Johnson is named on the cover responses. The filing shows voting and dispositive power entries tied to FMR LLC and references a power of attorney effective April 13, 2026, incorporated by reference.

Is the reported stake by FMR LLC considered over 5% for Centessa (CNTA)?

No. The filing explicitly states the holder's interest is for ownership of 5 percent or less of the class. The reported amount is 1,800 shares, which the filing lists as 0.0% of the outstanding common stock.

What exhibits or agreements are referenced in the Schedule 13G/A amendment?

The amendment references Exhibit 99 for a 13d-1(k)(1) agreement and incorporates a power of attorney by reference to an earlier filing. Exhibit cross-references are included in the cover information.

When was the Schedule 13G/A amendment signed for Centessa (CNTA)?

Signatures on the amendment are dated 07/07/2026. The cover page also lists an apparent reporting date of 06/30/2026 for the filing metadata and references a power of attorney effective 04/13/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 10:11 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

CENTESSA PHARMACEUTICALS PLC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

152309100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 152309100

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,800.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,800.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,800.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 152309100

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,800.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,800.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CENTESSA PHARMACEUTICALS PLC
(b)	Address of issuer's principal executive offices: 3RD FLOOR, 1 ASHLEY ROAD,ALTRINCHAM, CHESHIRE,X0,WA14 2DT
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 152309100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1800.00
(b)	Percent of class: 0.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 1800.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CENTESSA PHARMACEUTICALS PLC. No one other person's interest in the COMMON STOCK of CENTESSA PHARMACEUTICALS PLC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	07/07/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	07/07/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.